Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease

Bone Marrow Transplantation volume 34, pages 589–593 (2004)Cite this article

Summary:

During follow-up after allogeneic stem cell transplantation (SCT), patients frequently lose their immunity to infectious agents such as measles. The aim of this study was to analyze the influence of different factors on measles immunity. In total, 395 patients with a disease-free survival of at least 1 year were included. Measles vaccination was given at 2 years after SCT to children and young adults without chronic GVHD or ongoing immunosuppression. In all, 264 patients had matched sibling donors and 131 either mismatched family or unrelated donors. Totally, 318 patients received bone marrow and 77 peripheral blood stem cells. Overall, 375 patients had undergone myeloablative and 20 nonmyeloablative conditioning. Out of 395 patients, 133 (34%) were seronegative to measles. In multivariate models, younger age or being vaccinated to measles, rather than previous measles disease, before transplantation were risk factors both for becoming seronegative and to have doubtfully protective immunity to measles. Acute GVHD grade II–IV was a risk factor for seronegativity and blood stem cells a risk factor for doubtfully protective immunity. Children and young adults previously immunized to measles have a high risk for becoming vulnerable to a measles infection. Since measles is again circulating in many countries and measles is a serious infection after SCT, vaccination should be considered.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Ljungman P, Lewensohn-Fuchs I, Hammarstrom V et al. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood 1994; 84 (2): 657–663.

    CAS  PubMed  Google Scholar 

  2. Machado CM, Goncalves FB, Pannuti CS et al. Measles in bone marrow transplant recipients during an outbreak in Sao Paulo, Brazil. Blood 2002; 99 (1): 83–87.

    Article  CAS  PubMed  Google Scholar 

  3. Nakano T, Shimono Y, Sugiyama K et al. Clinical features of measles in immunocompromised children. Acta Paediatr Jpn 1996; 38 (3): 212–217.

    Article  CAS  PubMed  Google Scholar 

  4. Kaplan L, Daum R, Smaron M, McCarthy C . Severe measles in immunocompromised patients. JAMA 1992; 267 (9): 1237–1241.

    Article  CAS  PubMed  Google Scholar 

  5. Ringden O, Remberger M, Carlens S et al. Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies. Transplantation 1998; 66 (5): 620–625.

    Article  CAS  PubMed  Google Scholar 

  6. Ringdén O, Remberger M, Persson U et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15 (4): 619–625.

    PubMed  Google Scholar 

  7. Ringdén O, Pihlstedt P, Markling L et al. Prevention of graft-versus-host disease with T-cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991; 7: 221–226.

    PubMed  Google Scholar 

  8. Ljungman P, Fridell E, Lönnqvist B et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 1989; 159 (4): 610–615.

    Article  CAS  PubMed  Google Scholar 

  9. Ljungman P . Immunization of transplant recipients. Bone Marrow Transplant 1999; 23 (7): 635–636.

    Article  CAS  PubMed  Google Scholar 

  10. Remberger M, Kumlien G, Aschan J et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8 (12): 674–682.

    Article  PubMed  Google Scholar 

  11. Ringden O, Labopin M, Bacigalupo A et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002; 20 (24): 4655–4664.

    Article  CAS  PubMed  Google Scholar 

  12. Ringden O, Remberger M, Runde V et al. Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood 1999; 94 (2): 455–464.

    CAS  PubMed  Google Scholar 

  13. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97 (11): 3390–3400.

    Article  CAS  PubMed  Google Scholar 

  14. Update: global measles control and mortality reduction – worldwide. 1991–2001. MMWR – Morb Mortal Wkly Rep 2003; 52 (20): 471–475.

  15. Maris M, Boeckh M, Storer B et al. Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. Exp Hematol 2003; 31 (10): 941–952.

    Article  CAS  PubMed  Google Scholar 

  16. D'Sa S, Peggs K, Pizzey A et al. T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusions. Br J Haematol 2003; 123 (2): 309–322.

    Article  CAS  PubMed  Google Scholar 

  17. Kanra G, Cetin I, Akcoren Z et al. Giant cell pneumonia in a leukemic child in remission: a case report. Turk J Pediatr 2001; 43 (4): 338–341.

    CAS  PubMed  Google Scholar 

  18. Haltia M, Paetau A, Vaheri A et al. Fatal measles encephalopathy with retinopathy during cytotoxic chemotherapy. J Neurol Sci 1977; 32 (3): 323–330.

    Article  CAS  PubMed  Google Scholar 

  19. Breitfeld V, Hashida Y, Sherman F et al. Fatal measles infection in children with leukemia. Lab Invest 1973; 29: 279–281.

    Google Scholar 

  20. Measles epidemic attributed to inadequate vaccination coverage – Campania, Italy. 2002. MMWR – Morb Mortal Wkly Rep 2003; 53 (43): 1044–1047.

  21. Nakajima N, Matsuda T, Ono T et al. Measles outbreak in a suburb of Tokyo, Japan, in 1998–1999. Scand J Infect Dis 2003; 35 (8): 495–497.

    Article  PubMed  Google Scholar 

  22. McBrien J, Murphy J, Gill D et al. Measles outbreak in Dublin, 2000. Pediatr Infect Dis J 2003; 22 (7): 580–584.

    PubMed  Google Scholar 

  23. Anonymous. Measles pneumonitis following measles–mumps–rubella vaccination of a patient with HIV infection. MMWR – Morb Mort Weekly Rep 1996; 45 (28): 603–606.

  24. CDC. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR – Morb Mortal Wkly Rep 2000; 49 (RR-10): 1–125.

Download references

Acknowledgements

This study was supported by the Swedish Cancer Fund.

Author information

Authors and Affiliations

  1. Department of Hematology, Karolinska University Hospital/Huddinge, Stockholm, Sweden

    P Ljungman, J Aschan, L Barkholt, P-A Broliden, B Gustafsson, I Lewensohn-Fuchs, C Löfgren, J Winiarski & O Ringdén

Authors
  1. P Ljungman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Aschan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Barkholt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P-A Broliden
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Gustafsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I Lewensohn-Fuchs
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Löfgren
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Winiarski
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. O Ringdén
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Ljungman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ljungman, P., Aschan, J., Barkholt, L. et al. Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease. Bone Marrow Transplant 34, 589–593 (2004). https://doi.org/10.1038/sj.bmt.1704634

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704634

Keywords

This article is cited by

Search

Advanced search

Quick links